This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

10 Stocks Billionaire Steven Cohen Is Buying

BOSTON (TheStreet) -- Steven Cohen's SAC Capital, which has suffered catastrophic losses in biotechnology firm Dendreon (DNDN), made more mundane new purchases in the second quarter, including tractor maker Deere (DE).

Cohen's Stamford, Conn.-based hedge fund was founded in 1992 and has generated average annual returns of about 30%, according to The Wall Street Journal. As the largest investor in his own funds, Cohen usually earns more than $1 billion a year.

Steven A. Cohen (SAC Capital)

The hedge fund is known for its trading-oriented style to equities. For example, Cohen sold out of most of his position in Weight Watchers (WTW) during the second quarter after loading up a few months earlier. Cohen is now hoping his trading skills can dig him out of a hefty loss in his largest holding, Dendreon.

SAC Capital added to its position in Dendreon during the second quarter, lifting the stake by about 400,000 shares to 8.6 million as of June 30. However, Dendreon shares are down nearly 70% since June 30 after the company withdrew its 2011 revenue forecast due to slower-than-expected sales of its Provenge prostate cancer therapy.

Cohen, who has been at the center of an investigation by the Securities and Exchange Commission involving insider trading, is reportedly staring at losses of $200 million on the Dendreon position.

>>View SAC Capital's Portfolio

Hedge funds that manage more than $100 million are required to disclose their equity holdings, options and convertible debt on a Form 13F filed to the SEC within 45 days of the end of a quarter. Funds aren't required to report short positions betting on declines.

As SAC Capital is a long-short equity firm, it continued to trade heavily in equities during the second quarter, building up several new positions that Cohen will likely lean on now to make up the Dendreon losses. Overall, SAC Capital reported holdings in 2,033 securities as of June 30, 518 of which were new positions. The firm increased its ownership in 678 securities, including Apple (AAPL) and decreased positions in 730, such as Big Lots (BIG).

Cohen finally may have been bitten by the gold bug, as his hedge fund revealed in the filing that it owns options to buy shares of the SPDR Gold Trust (GLD). However, Cohen made other bets on several under-the-radar equities.

The following pages detail SAC Capital's 10 largest new equity positions in the second quarter, ranked by market value as of June 30.






10. Gen-Probe (GPRO)

Company Profile: Gen-Probe develops nucleic acid tests used to diagnose human diseases and to screen donated human blood.

Cohen's Investment: SAC Capital established a new position in Gen-Probe by buying up 268,000 shares of the company, which had a market value of roughly $18 million as of June 30.

Share Price Performance: The stock rose to a 52-week high of $86.96 in May but has been a losing investment since Cohen reported a stake. Shares of Gen-Probe are down nearly 12% since July 1.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

1 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,086.63 -26.91 -0.16%
S&P 500 1,987.01 +3.48 0.18%
NASDAQ 4,473.6970 +17.6810 0.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs